SYP and Alzheimer disease: In this study, the observed impact following Alirocumab administration on the synaptic markers synaptophysin and β3 tubulin could indicate that correcting systemic lipid imbalances enhances synaptic resilience and by extension delays the neurodegenerative cascade that underlies AD pathology and progression.